CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO

02-Aug-2010 - United Kingdom

CMP Therapeutics (CMPT) announced the appointment of Dr Neill Moray Mackenzie to the role of Chief Executive Officer. Dr Mackenzie brings to CMPT a long record of executive board level management within the biotechnology and pharmaceutical industries at companies including Cambridge genetics Ltd, Oxford BioMedica plc, Avidex Ltd (now Immunocore) and most recently as the SVP for business development and Corporate Strategy at MediGene AG and CEO of Roji Ltd (London). In addition, Dr MacKenzie was formerly a Departmental Head in Vaccine R&D at Wellcome and a Wellcome Lecturer in immunology at the University of London.

CMPT also announced the injection of a €1.5million convertible loan from Inventages Venture Capital to support continuing operations and the upcoming clinical trial of its lead product for the common cold. CMPT has been supported solely by investments from London-based Inventages Venture Capital and New Zealand-based BioPacificVentures since 2005.

Dr Bruce Savage, the former CEO, leaves CMPT to concentrate on his other portfolio companies.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances